New oral drug MRX-2843 tested in Hard-to-Treat leukemias

NCT ID NCT04872478

Recruiting now Disease control Sponsor: Meryx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing an experimental oral drug called MRX-2843 in adolescents and adults whose acute leukemia (AML, ALL, or mixed phenotype) has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 50 participants will take MRX-2843 capsules daily in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRX-2843 (oral capsules)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat leukemias that have come back or not responded to standard therapy.
What could go wrong: This is a very early (Phase 1) trial with only 50 participants, so it is primarily checking safety and dosing, not yet proving effectiveness. The drug may cause side effects or not work at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia acute myeloid leukemia mixed phenotype acute leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA MIXED PHENOTYPE ACUTE LEUKEMIA

Contacts and locations

Locations

Emory University - WINSHIP Cancer Center
RECRUITING

Atlanta, Georgia, 30322, United States
Emory University, Children's Healthcare of Atlanta
RECRUITING

Atlanta, Georgia, 30322, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.